Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
12 October 2018Website:
http://www.equilliumbio.comNext earnings report:
25 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | 12 min agoDividend
Analysts recommendations
Institutional Ownership
EQ Latest News
Equillium, Inc. (EQ) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to loss of $0.10 per share a year ago.
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced second quarter 2024 estimated ending cash, cash equivalents and short-term investments of approximately $33.3 million, representing an increase of approximately $1.0 million from the end of the first quarter of 2024. The increase is primarily the result of receiving a tax credit of.
Equillium, Inc. (EQ) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.08 per share a year ago.
Amid the broad-market rally, shares of Equillium (EQ), Phunware (PHUN), Super Micro Computer (SMCI), Vaxart (VXRT) and Dianthus Therapeutics (DNTH) have more than doubled this year.
Equillium, Inc. (EQ) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.41 per share a year ago.
What type of business is Equillium?
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. Equillium, Inc. has a research collaboration agreement with Vivtex Corporation to develop GI-targeted formulations for Bi-specific peptide therapy. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
What sector is Equillium in?
Equillium is in the Healthcare sector
What industry is Equillium in?
Equillium is in the Biotechnology industry
What country is Equillium from?
Equillium is headquartered in United States
When did Equillium go public?
Equillium initial public offering (IPO) was on 12 October 2018
What is Equillium website?
https://www.equilliumbio.com
Is Equillium in the S&P 500?
No, Equillium is not included in the S&P 500 index
Is Equillium in the NASDAQ 100?
No, Equillium is not included in the NASDAQ 100 index
Is Equillium in the Dow Jones?
No, Equillium is not included in the Dow Jones index
When was Equillium the previous earnings report?
No data
When does Equillium earnings report?
The next expected earnings date for Equillium is 25 March 2025